What Phase III Trials Are Needed to Improve the Treatment of Advanced Non-Small-Cell Lung Cancer?

Nature Clinical Practice Oncology

doi 10.1038/ncponc0199

Full Text

Abstract

Available in

Date

Authors

Publisher

Springer Science and Business Media LLC

Related search

Targeting Angiogenesis in Advanced Non-Small-Cell Lung Cancer: Are Biomarkers Needed?

Current Respiratory Care Reports
2013English

Afatinib Treatment in Advanced Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2011English

Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systemic Review

PLoS ONE
Multidisciplinary
2011English

Targeted Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2005English

Are We Really Operating on Advanced Stage Non-Small Cell Lung Cancer?

Journal of Thoracic and Cardiovascular Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2019English

OA04.01 What Is the Cost of a Strong Evidence for the Treatment of Advanced Non-Small Cell Lung Cancer?

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Single‐Agent Paclitaxel in the Treatment of Advanced Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
1999English

Sequential Treatment of Tyrosine Kinase Inhibitors and Chemotherapy for EGFR-mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Phase III Trials

OncoTargets and Therapy
OncologyPharmacology
2013English

Redefining Treatment Paradigms in First-Line Advanced Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy